[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355072-105":59,"doc-detail-355072-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","psammaplysene-d-overcomes-sorafenib-resistance-in-liver-cancer-by-targeting-fgfr4cyp26a1-retinoic-acid-axis-to-drive-ferroptosis","Psammaplysene D overcomes sorafenib resistance in liver cancer by targeting FGFR4/CYP26A1-retinoic acid axis to drive ferroptosis","","Psammaplysene D is evaluated as a novel therapeutic compound for overcoming sorafenib resistance in liver cancer, either alone or combined with sorafenib. Efficacy is tested in liver cancer cell lines and xenograft mouse models, including sorafenib-resistant variants. Direct interaction with FGFR4 is confirmed using molecular docking and CETSA, while RNA-seq identifies key gene changes. Ferroptosis induction is assessed by marker analysis and validated via genetic and pharmacological methods, revealing a FGFR4/CYP26A1-retinoic acid axis that drives ferroptosis in resistant settings.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/psammaplysene-d-overcomes-sorafenib-resistance-in-liver-cancer-by-targeting-fgfr4cyp26a1-retinoic-acid-axis-to-drive-ferroptosis/355072/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/psammaplysene-d-overcomes-sorafenib-resistance-in-liver-cancer-by-targeting-fgfr4cyp26a1-retinoic-acid-axis-to-drive-ferroptosis/355072.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study’s main goal for Psammaplysene D in liver cancer?","Question",{"text":112,"@type":113},"To determine whether Psammaplysene D can overcome sorafenib resistance in liver cancer, used alone or together with sorafenib.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do the researchers confirm that Psammaplysene D directly targets FGFR4?",{"text":117,"@type":113},"They use molecular docking and Cellular Thermal Shift Assay (CETSA) to verify direct binding between Psammaplysene D and FGFR4.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism links Psammaplysene D treatment to ferroptosis in resistant liver cancer?",{"text":121,"@type":113},"Psammaplysene D targets FGFR4, downregulates CYP26A1 in resistant cells, increases retinoic acid (RA), and the resulting RA-driven ferroptosis reduces tumor growth.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355072,1790362866,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":26,"preview_page_count":19,"preview_urls":145},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Yang et al. Journal of Experimental & Clinical Cancer Research (2026) 45:44 [https://doi.org/10.1186/s13046-025-03622-1](https://doi.org/10.1186/s13046-025-03622-1)  \nJournal of Experimental & Clinical Cancer Research  \nRESEARCH Open Access  \nPsammaplysene D overcomes sorafenib  resistance in liver cancer by targeting FGFR4/ CYP26A1-retinoic acid axis to drive ferroptosis  \nTing Yang1, Yanlu Han1, Yuting Wang1, Ruyu Li1, Xiaonan Zhang2, Xinxin Zhang2, Xiaohan Xu1, Jing Xu3, Xiaoyu Li3*, Chunhua Lin4*, Wen Wang5* and Jinbo Yang1,2*  \nAbstract  \nBackground Overcoming sorafenib resistance remains a major challenge in liver cancer treatment. This study evaluates the novel compound Psammaplysene D, alone or combined with sorafenib, against liver cancer, focusing on overcoming resistance.  \nMethods The efficacy of Psammaplysene D, alone or with sorafenib, was assessed using liver cancer cell lines and xenograft mouse models, including sorafenib-resistant variants. The direct binding interaction between Psammaplysene D and FGFR4 was confirmed through molecular docking and Cellular Thermal Shift Assay (CETSA) . Transcriptomic profiling (RNA-seq) identified key differentially expressed genes. Ferroptosis induction was evaluated using key markers, and functional roles were validated using genetic and pharmacological approaches.  \nResults Psammaplysene D inhibited liver cancer growth in vitro and in vivo, alone or synergistically with sorafenib, and overcame sorafenib resistance in both models. Mechanistic investigations revealed that Psammaplysene D directly targets FGFR4, inducing ferroptosis. In sorafenib-resistant cells, Psammaplysene D downregulates CYP26A1 expression, elevating retinoic acid (RA) levels. FGFR4 inhibition triggered ferroptosis and reduced CYP26A1 expression, while accumulated RA drove ferroptosis in resistant cells.  \nConclusions Overall, Psammaplysene D is a potent therapeutic agent for liver cancer, effective alone or combined with sorafenib, and overcomes resistance through direct targeting of FGFR4, initiating a cascade of CYP26A1 downregulation, RA accumulation, and ferroptosis induction-defining a novel FGFR4/CYP26A1/RA axis regulating ferroptosis in resistant liver cancer.  \nHighlights  \nPsammaplysene D overcomes sorafenib resistance in liver cancer by inducing ferroptosis through targeting FGFR4 .  \n*Correspondence:  \nXiaoyu Li[lixiaoyu05@163.com](lixiaoyu05@163.com)[ ](lixiaoyu05@163.com)Chunhua Lin [chunhua.Lin@qdu.edu.cn](chunhua.Lin@qdu.edu.cn)[ ](chunhua.Lin@qdu.edu.cn)Wen Wang [ww028296@qlyyqd.com](ww028296@qlyyqd.com)[ ](ww028296@qlyyqd.com)Jinbo Yang [yangjb@ouc.edu.cn](yangjb@ouc.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The)[. The](http://creativecommons.org/licenses/by/4.0/. The)[ ](http://creativecommons.org/licenses/by/4.0/. The)Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated","cbCaip7WaKi64Vzz","https://ap.wps.com/l/cbCaip7WaKi64Vzz","pdf",15268892,24,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Highlights\n# Introduction\n# Keywords","[{\"question\":\"What is the study’s main goal for Psammaplysene D in liver cancer?\",\"answer\":\"To determine whether Psammaplysene D can overcome sorafenib resistance in liver cancer, used alone or together with sorafenib.\"},{\"question\":\"How do the researchers confirm that Psammaplysene D directly targets FGFR4?\",\"answer\":\"They use molecular docking and Cellular Thermal Shift Assay (CETSA) to verify direct binding between Psammaplysene D and FGFR4.\"},{\"question\":\"What mechanism links Psammaplysene D treatment to ferroptosis in resistant liver cancer?\",\"answer\":\"Psammaplysene D targets FGFR4, downregulates CYP26A1 in resistant cells, increases retinoic acid (RA), and the resulting RA-driven ferroptosis reduces tumor growth.\"}]","Psammaplysene D overcomes sorafenib resistance in liver cancer by targeting FGFR4/CYP26A1-retinoic acid axis to drive ferroptosis | PDF",1790115736,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91eefbb656add16ffc1569e1e2c3a692.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a3e2a2bd97eea2ab383e1c0397e62ad.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e796355150f1abb2fe6ceecfdd6e43c9.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/89bb3bf4dc8a7a24c6d66a6f753d1910.webp",980,1306]